CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
Yellow Fever Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04269265
NCT04269265Phase 2Completed
CompareCT.gov

The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination

University of Minnesota·interventional·Posted Feb 13, 2020·Updated Oct 7, 2025

In Brief

A Phase 2 clinical trial evaluating Yellow Fever Vaccine for Yellow Fever. Completed, enrolled 43 participants across 2 sites in 2 countries.

Detailed Summary

Hypothesis: Infections other than HIV can cause LN inflammation and collagen damage to the fibroblastic reticular cell network (FRCn), which will lead to CD4 T cell depletion and impaired vaccine responses. This protocol will study yellow fever vaccine (YFV) in two cohorts of people, one from Uganda and the other from Minnesota where we collect lymphoid tissues (LT) and peripheral blood monocytes (PBMCs) before and after vaccination using a new technique to catalog infectious burden of the individual, determine the relationship between IA, Infections, and immune response.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsYellow Fever
CountriesUganda, United States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 13, 2020
Enrollment StartJul 1, 2020
Primary CompletionOct 23, 2023
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 6.4 years ago

Interventions

Yellow Fever Vaccinebiological

YF-VAX®, Yellow Fever Vaccine, for subcutaneous use